Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK.
Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK.
J Autoimmun. 2021 Jul;121:102662. doi: 10.1016/j.jaut.2021.102662. Epub 2021 May 19.
Herein, we consider venous immunothrombotic mechanisms in SARS-CoV-2 infection and anti-SARS-CoV-2 DNA vaccination. Primary SARS-CoV-2 infection with systemic viral RNA release (RNAaemia) contributes to innate immune coagulation cascade activation, with both pulmonary and systemic immunothrombosis - including venous territory strokes. However, anti-SARS-CoV-2 adenoviral-vectored-DNA vaccines -initially shown for the ChAdOx1 vaccine-may rarely exhibit autoimmunity with autoantibodies to Platelet Factor-4 (PF4) that is termed Vaccine-Induced Thrombotic Thrombocytopenia (VITT), an entity pathophysiologically similar to Heparin-Induced Thrombocytopenia (HIT). The PF4 autoantigen is a polyanion molecule capable of independent interactions with negatively charged bacterial cellular wall, heparin and DNA molecules, thus linking intravascular innate immunity to both bacterial cell walls and pathogen-derived DNA. Crucially, negatively charged extracellular DNA is a powerful adjuvant that can break tolerance to positively charged nuclear histone proteins in many experimental autoimmunity settings, including SLE and scleroderma. Analogous to DNA-histone interactons, positively charged PF4-DNA complexes stimulate strong interferon responses via Toll-Like Receptor (TLR) 9 engagement. A chain of events following intramuscular adenoviral-vectored-DNA vaccine inoculation including microvascular damage; microbleeding and platelet activation with PF4 release, adenovirus cargo dispersement with DNA-PF4 engagement may rarely break immune tolerance, leading to rare PF4-directed autoimmunity. The VITT cavernous sinus cerebral and intestinal venous territory immunothrombosis proclivity may pertain to venous drainage of shared microbiotal-rich areas of the nose and in intestines that initiates local endovascular venous immunity by PF4/microbiotal engagement with PF4 autoantibody driven immunothrombosis reminiscent of HIT. According to the proposed model, any adenovirus-vectored-DNA vaccine could drive autoimmune VITT in susceptible individuals and alternative mechanism based on molecular mimicry, vaccine protein contaminants, adenovirus vector proteins, EDTA buffers or immunity against the viral spike protein are secondary factors. Hence, electrochemical DNA-PF4 interactions and PF4-heparin interactions, but at different locations, represent the common denominator in HIT and VITT related autoimmune-mediated thrombosis.
在这里,我们考虑了 SARS-CoV-2 感染和抗 SARS-CoV-2 DNA 疫苗接种中的静脉免疫血栓形成机制。伴有全身病毒 RNA 释放(RNAaemia)的原发性 SARS-CoV-2 感染导致固有免疫凝血级联激活,包括肺和全身免疫血栓形成-包括静脉区域中风。然而,最初在 ChAdOx1 疫苗中显示的抗 SARS-CoV-2 腺病毒载体-DNA 疫苗可能会很少表现出自身免疫性,对血小板因子-4(PF4)产生自身抗体,这被称为疫苗诱导的血栓性血小板减少症(VITT),其病理生理学与肝素诱导的血小板减少症(HIT)相似。PF4 自身抗原是一种多阴离子分子,能够与带负电荷的细菌细胞壁、肝素和 DNA 分子独立相互作用,从而将血管内固有免疫与细菌细胞壁和病原体衍生的 DNA 联系起来。至关重要的是,带负电荷的细胞外 DNA 是一种强大的佐剂,它可以打破许多实验性自身免疫环境中对带正电荷的核组蛋白蛋白的耐受性,包括系统性红斑狼疮和硬皮病。类似于 DNA-组蛋白相互作用,带正电荷的 PF4-DNA 复合物通过 Toll 样受体(TLR)9 结合刺激强烈的干扰素反应。腺病毒载体-DNA 疫苗接种后一系列事件包括微血管损伤;血小板激活和 PF4 释放,腺病毒货物分散与 PF4-DNA 结合可能很少打破免疫耐受性,导致罕见的 PF4 定向自身免疫。VITT 海绵窦脑和肠道静脉区域免疫血栓形成倾向可能与鼻子和肠道中富含微生物群的区域的静脉引流有关,这些区域通过 PF4/微生物群与 PF4 自身抗体驱动的免疫血栓形成结合启动局部血管内静脉免疫,类似于 HIT。根据提出的模型,任何腺病毒载体-DNA 疫苗都可能在易感个体中引发自身免疫性 VITT,而基于分子模拟、疫苗蛋白污染物、腺病毒载体蛋白、EDTA 缓冲液或针对病毒刺突蛋白的免疫的替代机制是次要因素。因此,电化学 DNA-PF4 相互作用和 PF4-肝素相互作用,但在不同的位置,代表了 HIT 和 VITT 相关自身免疫性血栓形成的共同点。